Evidence map›Paper›PMID 27479743›Full record

ArticleNature chemical biology2016

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition.

Aaron Boudreau, Hans E Purkey, Anna Hitz, Kirk Robarge, David Peterson, Sharada Labadie, Mandy Kwong, Rebecca Hong, Min Gao, Christopher Del Nagro and 25 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 258 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 1 institution in 1 country.

Aaron BoudreauDiscovery Oncology, Genentech, South San Francisco, California, USA.
Hans E PurkeyDiscovery Chemistry, Genentech, South San Francisco, California, USA.
Anna HitzTranslational Oncology, Genentech, South San Francisco, California, USA.
Kirk RobargeDiscovery Chemistry, Genentech, South San Francisco, California, USA.
David PetersonDiscovery Oncology, Genentech, South San Francisco, California, USA.
Sharada LabadieDiscovery Chemistry, Genentech, South San Francisco, California, USA.
Mandy KwongTranslational Oncology, Genentech, South San Francisco, California, USA.
Rebecca HongTranslational Oncology, Genentech, South San Francisco, California, USA.
Min GaoTranslational Oncology, Genentech, South San Francisco, California, USA.
Christopher Del NagroTranslational Oncology, Genentech, South San Francisco, California, USA.
Raju PusapatiDiscovery Oncology, Genentech, South San Francisco, California, USA.
Shuguang MaDrug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA.
Laurent SalphatiDrug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA.
Jodie PangDrug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA.
Aihe ZhouDiscovery Chemistry, Genentech, South San Francisco, California, USA.
Tommy LaiChemistry, WuXi AppTec Co., Ltd., Shanghai, China.
Yingjie LiStructural Biology, WuXi AppTec Co., Ltd., Shanghai, China.
Zhongguo ChenStructural Biology, WuXi AppTec Co., Ltd., Shanghai, China.
Binqing WeiDiscovery Chemistry, Genentech, South San Francisco, California, USA.
Ivana YenBiochemical and Cellular Pharmacology, Genentech, South San Francisco, California, USA.
Steve SiderisBiochemical and Cellular Pharmacology, Genentech, South San Francisco, California, USA.
Mark McClelandDepartment of Pathology, Genentech, South San Francisco, California, USA.
Ron FiresteinDepartment of Pathology, Genentech, South San Francisco, California, USA.
Laura CorsonTranslational Oncology, Genentech, South San Francisco, California, USA.
Alex VanderbiltBiomedical Imaging, Genentech, South San Francisco, California, USA.
Simon WilliamsBiomedical Imaging, Genentech, South San Francisco, California, USA.
Anneleen DaemenBioinformatics, Genentech, South San Francisco, California, USA.
Marcia BelvinTranslational Oncology, Genentech, South San Francisco, California, USA.
Charles EigenbrotStructural Biology, Genentech, South San Francisco, California, USA.
Peter K JacksonTranslational Oncology, Genentech, South San Francisco, California, USA.
Shiva MalekBiochemical and Cellular Pharmacology, Genentech, South San Francisco, California, USA.
Georgia HatzivassiliouTranslational Oncology, Genentech, South San Francisco, California, USA.
Deepak SampathTranslational Oncology, Genentech, South San Francisco, California, USA.
Marie EvangelistaDiscovery Oncology, Genentech, South San Francisco, California, USA.
Thomas O'BrienTranslational Oncology, Genentech, South San Francisco, California, USA.
WuXi AppTec (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic reprogramming in tumors represents a potential therapeutic target. Herein we used shRNA depletion and a novel lactate dehydrogenase (LDHA) inhibitor, GNE-140, to probe the role of LDHA in tumor growth in vitro and in vivo. In MIA PaCa-2 human pancreatic cells, LDHA inhibition rapidly affected global metabolism, although cell death only occurred after 2 d of continuous LDHA inhibition. Pancreatic cell lines that utilize oxidative phosphorylation (OXPHOS) rather than glycolysis were inherently resistant to GNE-140, but could be resensitized to GNE-140 with the OXPHOS inhibitor phenformin. Acquired resistance to GNE-140 was driven by activation of the AMPK-mTOR-S6K signaling pathway, which led to increased OXPHOS, and inhibitors targeting this pathway could prevent resistance. Thus, combining an LDHA inhibitor with compounds targeting the mitochondrial or AMPK-S6K signaling axis may not only broaden the clinical utility of LDHA inhibitors beyond glycolytically dependent tumors but also reduce the emergence of resistance to LDHA inhibition.

Indexed as

Cell DeathCell Line, TumorCell PlasticityCell ProliferationDose-Response Relationship, DrugEnzyme InhibitorsHumansL-Lactate DehydrogenaseModels, MolecularMolecular StructurePyridonesStructure-Activity RelationshipThiophenesEnzyme InhibitorsGNE-140L-Lactate DehydrogenasePyridonesThiophenes

Identifiers

PMID27479743
OpenAlexW2488631284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.